Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID: A Pilot Study Targeting Fatigue and Neurocognitive Symptoms

NCT06821087 is registered in ClinicalTrials.gov with University of Texas at Austin as lead sponsor.

NCT NCT06821087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06821087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID: A Pilot Study Targeting Fatigue and Neurocognitive Symptoms
Lead sponsor
University of Texas at Austin
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2025
Completion date
June 22, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long covid